Royal Bank of Canada’s Vertex Pharmaceuticals VRTX Stock Holding History

Royal Bank of Canada’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-500	Closed	-$209K	–	7583
2024 Q1	$209K	Buy	+500	New	+$211K	﹤0.01%	4655
2017 Q1	–	Sell	-20,000	Closed	-$1.47M	–	6843
2016 Q4	$1.47M	Hold	20,000	–	–	﹤0.01%	2824
2016 Q3	$1.74M	Sell	20,000 -30,000	-60%	-$2.84M	﹤0.01%	2650
2016 Q2	$4.3M	Sell	50,000 -10,000	-17%	-$864K	﹤0.01%	1999
2016 Q1	$4.77M	Buy	60,000 +38,900	+184%	+$3.52M	﹤0.01%	1860
2015 Q4	$2.65M	Hold	21,100	–	–	﹤0.01%	2306
2015 Q3	$2.2M	Hold	21,100	–	–	﹤0.01%	2195
2015 Q2	$2.6M	Buy	+21,100	New	+$2.66M	﹤0.01%	2107
2013 Q3	–	Sell	-35,000	Closed	-$2.79M	–	6276
2013 Q2	$2.79M	Buy	+35,000	New	+$2.58M	﹤0.01%	1840

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Royal Bank of Canada's VRTX Position: Q1 2026 in Review

Royal Bank of Canada reduced its Vertex Pharmaceuticals (VRTX) stake by 6.9% in Q1 2026, selling an estimated $38.5M and leaving 1,111,871 shares worth $496M. The position accounts for 0.09% of the portfolio, ranked #218.

Royal Bank of Canada first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $788M in Q2 2024. 1,692 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Royal Bank of Canada held 1,111,871 shares of Vertex Pharmaceuticals worth $496M as of Q1 2026.
Royal Bank of Canada sold 82,641 Vertex Pharmaceuticals shares in Q1 2026, an estimated $38.5M.
Vertex Pharmaceuticals made up 0.09% of Royal Bank of Canada's portfolio in Q1 2026, its #218 holding.
Royal Bank of Canada first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Royal Bank of Canada's Vertex Pharmaceuticals position peaked at $788M in Q2 2024.
1,692 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.